CHELSEA, Mass. -- (BUSINESS WIRE) -- Civitas Therapeutics, Inc., a privately-held biopharmaceutical company with a lead program in Parkinson’s disease that leverages the proprietary ARCUS(TM) respiratory delivery platform, today announced its participation at the 21st Annual Future Leaders in the Biotech Industry Conference to be held at the Millennium Broadway Hotel & Conference Center in New York City on March 28, 2014.
|Speaker:||Mark Iwicki, President & Chief Executive Officer|
|Date:||March 28, 2014|
|Time:||3:10 pm EDT|
|Location:||Room 508, Millennium Broadway Hotel & Conference Center|
About Civitas Therapeutics
Civitas Therapeutics is a privately-held biopharmaceutical company focused on developing a robust pipeline of inhaled therapeutics with the clinically-proven ARCUS(TM) dry powder pulmonary delivery platform. The company’s lead program, CVT-301, is being developed as adjunctive, on-demand (PRN) therapy to provide Parkinson’s disease patients with rapid and reliable relief from intermittent debilitating motor fluctuations (OFF episodes). In April 2013, Civitas announced positive results for CVT-301 in a Phase 2a dose-ranging study. The company has completed enrollment of a Phase 2b study to evaluate the efficacy and safety of CVT-301 in treating emergent OFF episodes during one month of continued use, with data expected by April 2014. The Company’s pipeline also includes products for respiratory disease, central nervous system disorders and infectious disease.
The ARCUS(TM) platform is a proprietary dry powder and device combination with a unique ability to deliver a large, precise dose independent of inspiratory flow rate from a simple, breath actuated device and is protected by a large intellectual property estate. The Company is financed by leading investors including Alkermes plc, Bay City Capital, Canaan Partners, Fountain Healthcare Partners, Longitude Capital and RA Capital. For further information on Civitas, please visit www.civitastherapeutics.com.